Charles Silberstein M.D., CFA
Net Worth
Last updated:
What is Charles Silberstein M.D., CFA net worth?
The estimated net worth of Dr. Charles Silberstein M.D., CFA is at least $1,556,157 as of 8 Jun 2021. He owns shares worth $43,357 as insider and has received compensation worth at least $1,512,800 in Applied Therapeutics, Inc..
What is the salary of Charles Silberstein M.D., CFA?
Dr. Charles Silberstein M.D., CFA salary is $378,200 per year as Chief Financial Officer & Head of Bus. Devel. in Applied Therapeutics, Inc..
How old is Charles Silberstein M.D., CFA?
Dr. Charles Silberstein M.D., CFA is 54 years old, born in 1971.
What stocks does Charles Silberstein M.D., CFA currently own?
As insider, Dr. Charles Silberstein M.D., CFA owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Applied Therapeutics, Inc. (APLT) | Chief Financial Officer & Head of Bus. Devel. | 87,803 | $0.49 | $43,357 |
What does Applied Therapeutics, Inc. do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Charles Silberstein M.D., CFA insider trading
Applied Therapeutics, Inc.
Dr. Charles Silberstein M.D., CFA has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 5,047 units of APLT stock on 8 Jun 2021.
As of 8 Jun 2021 he still owns at least 87,803 units of APLT stock.
Applied Therapeutics key executives
Applied Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Charles Silberstein M.D., CFA (54) Chief Financial Officer & Head of Bus. Devel.
- Dr. Riccardo Perfetti (66) Chief Medical Officer
- Dr. Shoshana Shendelman Ph.D. (46) Chair of the Board of Directors, Founder, Pres, Chief Executive Officer & Sec.